# A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

> **NCT05538130** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 124 (estimated)

## Conditions studied

- Melanoma
- Glioma
- Thyroid Cancer
- Non-Small Cell Lung Cancer
- Malignant Neoplasms
- Brain Neoplasms
- Advanced or Metastatic Solid Tumors
- HGG
- LGG
- Low Grade Glioma
- High Grade Glioma
- Differentiated Thyroid Cancer
- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** PF-07799544
- **DRUG:** PF-07799933

## Key facts

- **NCT ID:** NCT05538130
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-30
- **Primary completion:** 2027-08-09
- **Final completion:** 2029-02-07
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05538130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05538130, "A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05538130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*